Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Generic Drug Review Costs Still Largely Non-Personnel Related

Executive Summary

Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.


Related Content

GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Risk-Based Inspections Might Actually Be Hurting Compliant Firms
FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says
FDA’s Rent Is Too Damn High: Consolidated Labs Cost More Than Off-Campus Space
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections